In an astounding feature, “The Empire of Edge,” the New Yorker last month chronicled the bizarre tale of how the U-M Alzheimer’s expert leaked secret drug trial results to Wall Street trader Mathew Martoma. Martoma’s employer, SAC Capital Advisors, gained an estimated $276 million trading on the information. But reporter Patrick Radden Keefe, while brilliantly tracing Martoma’s backstory, had no more luck than the Observer had in understanding Gilman’s baffling ethical lapse (“The Corruption of Sid Gilman,” January 2013).

Gilman forfeited $234,000, but escaped a likely prison sentence by testifying against Martoma. Keefe, who attended the trial in Manhattan last fall, told the Observer he found Gilman’s testimony unreliable–he thought he saw signs, ironically, of dementia. But Martoma was convicted and in September was sentenced to nine years in prison–one of the harshest penalties ever imposed for insider trading. Though SAC founder Steven A. Cohen has eluded prosecutors, the company itself pled guilty; it’s paid the government about $1.8 billion in fines and a civil settlement.

Like the Observer, the New Yorker didn’t find a single local physician willing to talk about their former colleague. The U-M Health System has long since scrubbed Gilman’s name from the neurology service, Alzheimer’s center, and lecture series once named for the disgraced doctor. But it lives on, in his many books–including, it seems, one due to be published in January.

Joel Vilensky, a medical professor in Fort Wayne, says that Gilman did contribute to The Cranial Nerves, but their collaboration ended three years ago, before the scandal erupted, and he’s since been replaced by another writer. The publisher, however, apparently hasn’t yet gotten the word that Gilman’s name is poison: in mid-October it still listed Gilman as co-author.